Bayer warns against compulsory licensing in India as Natco builds case for Nexavar
This article was originally published in Scrip
Executive Summary
Faced with the prospect of a compulsory licence against its anticancer Nexavar (sorafenib tosylate) in India, Bayer has said that the extensive use of such licenses will "undermine and threaten" the patent system that fosters innovation.